CS
OMED

Credit Suisse’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Credit Suisse’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-44,484
Closed -$149K – 4360
2017
Q2 		$149K Sell
44,484
-38,846
-47% -$161K ﹤0.01% 3677
2017
Q1 		$767K Sell
83,330
-8,616
-9% -$75.7K ﹤0.01% 3053
2016
Q4 		$709K Buy
91,946
+125
+0.1% +$1.15K ﹤0.01% 3259
2016
Q3 		$1.05M Sell
91,821
-15,708
-15% -$183K ﹤0.01% 2915
2016
Q2 		$1.32M Buy
107,529
+24,666
+30% +$299K ﹤0.01% 2678
2016
Q1 		$838K Buy
82,863
+3,140
+4% +$36.9K ﹤0.01% 2857
2015
Q4 		$1.8M Sell
79,723
-2,700
-3% -$55.3K ﹤0.01% 2358
2015
Q3 		$1.37M Sell
82,423
-27,985
-25% -$561K ﹤0.01% 2546
2015
Q2 		$2.48M Buy
110,408
+28,617
+35% +$706K ﹤0.01% 2365
2015
Q1 		$2.11M Buy
81,791
+61,045
+294% +$1.55M ﹤0.01% 2355
2014
Q4 		$451K Buy
20,746
+7,822
+61% +$160K ﹤0.01% 3788
2014
Q3 		$244K Sell
12,924
-13,362
-51% -$269K ﹤0.01% 4038
2014
Q2 		$612K Buy
26,286
+13,757
+110% +$340K ﹤0.01% 3688
2014
Q1 		$422K Buy
+12,529
New +$422K ﹤0.01% 3841

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Credit Suisse's OMED Position: Q3 2017 in Review

Credit Suisse sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2017, closing a stake of 44,484 shares — an estimated $149K sold.

Credit Suisse first reported a position in OMED in Q1 2014 and held it in 14 quarters. The position peaked at $2.48M in Q2 2015. 58 funds tracked by Wall St. Rank hold OMED as of Q3 2017.

  • Credit Suisse reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Credit Suisse sold 44,484 OncoMed Pharmaceuticals, Inc. shares in Q3 2017, an estimated $149K.
  • Credit Suisse first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2014 and held it in 14 quarters.
  • Credit Suisse's OncoMed Pharmaceuticals, Inc. position peaked at $2.48M in Q2 2015.
  • 58 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2017.

Based on Credit Suisse's 13F filing for Q3 2017, filed 14 Nov 2017.